Net Income (Loss) Attributable to Parent in USD of Cocrystal Pharma, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cocrystal Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Cocrystal Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$2.05M, a 58.5% increase year-over-year.
  • Cocrystal Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$9.67M, a 48.3% increase year-over-year.
  • Cocrystal Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$17.5M, a 2.67% increase from 2023.
  • Cocrystal Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$18M, a 53.7% increase from 2022.
  • Cocrystal Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$38.8M, a 174% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Cocrystal Pharma, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$9.67M -$2.05M +$2.89M +58.5% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$12.6M -$2.06M +$3.29M +61.5% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$15.8M -$2.3M +$1.66M +41.8% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$17.5M -$3.27M +$1.2M +26.8% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025
Q3 2024 -$18.7M -$4.94M -$774K -18.6% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$17.9M -$5.34M -$1.18M -28.3% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$16.8M -$3.96M +$1.23M +23.8% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$18M -$4.46M +$37K +0.82% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025
Q3 2023 -$18M -$4.17M +$1.54M +26.9% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 -$19.6M -$4.17M +$20.3M +82.9% 01 Apr 2023 30 Jun 2023 10-Q 13 Nov 2024
Q1 2023 -$39.8M -$5.19M -$981K -23.3% 01 Jan 2023 31 Mar 2023 10-Q 13 Nov 2024
Q4 2022 -$38.8M -$4.5M -$816K -22.1% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$38M -$5.7M -$1.76M -44.6% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 -$36.3M -$24.4M -$20.6M -539% 01 Apr 2022 30 Jun 2022 10-Q 13 Nov 2023
Q1 2022 -$15.7M -$4.21M -$1.47M -53.7% 01 Jan 2022 31 Mar 2022 10-Q 13 Nov 2023
Q4 2021 -$14.2M -$3.69M -$2.19M -147% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023
Q3 2021 -$12M -$3.94M -$1.27M -47.6% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$10.7M -$3.82M -$326K -9.33% 01 Apr 2021 30 Jun 2021 10-Q 14 Nov 2022
Q1 2021 -$10.4M -$2.74M -$748K -37.6% 01 Jan 2021 31 Mar 2021 10-Q 14 Nov 2022
Q4 2020 -$9.65M -$1.49M +$46.4M +96.9% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022
Q3 2020 -$56M -$2.67M -$890K -50% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$55.1M -$3.5M -$1.98M -131% 01 Apr 2020 30 Jun 2020 10-Q 15 Nov 2021
Q1 2020 -$53.1M -$1.99M -$4.96M -167% 01 Jan 2020 31 Mar 2020 10-Q 15 Nov 2021
Q4 2019 -$48.2M -$47.8M -$3.56M -8.04% 01 Oct 2019 31 Dec 2019 10-K 17 Mar 2021
Q3 2019 -$44.6M -$1.78M +$88K +4.71% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$44.7M -$1.52M -$172K -12.8% 01 Apr 2019 30 Jun 2019 10-Q 13 Nov 2020
Q1 2019 -$44.5M $2.97M +$4.52M 01 Jan 2019 31 Mar 2019 10-Q 13 Nov 2020
Q4 2018 -$49M -$44.3M -$49.2M -1004% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020
Q3 2018 $135K -$1.87M +$92K +4.69% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $43K -$1.34M +$917K +40.6% 01 Apr 2018 30 Jun 2018 10-Q 12 Nov 2019
Q1 2018 -$874K -$1.55M +$997K +39.1% 01 Jan 2018 31 Mar 2018 10-Q 12 Nov 2019
Q4 2017 -$1.87M $4.9M +$70.7M 01 Oct 2017 31 Dec 2017 10-K 21 Mar 2018
Q3 2017 -$72.5M -$1.96M -$79K -4.2% 01 Jul 2017 30 Sep 2017 10-K 21 Mar 2018
Q2 2017 -$72.4M -$2.26M +$967K +30% 01 Apr 2017 30 Jun 2017 10-Q 09 Nov 2018
Q1 2017 -$73.4M -$2.55M +$1.46M +36.5% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$74.9M -$65.8M -$35.3M -116% 01 Oct 2016 31 Dec 2016 10-K 21 Mar 2018
Q3 2016 -$39.6M -$1.88M -$1.37M -270% 01 Jul 2016 30 Sep 2016 10-K 21 Mar 2018
Q2 2016 -$38.2M -$3.23M -$604K -23% 01 Apr 2016 30 Jun 2016 10-K 21 Mar 2018
Q1 2016 -$37.6M -$4.01M +$12.5M +75.7% 01 Jan 2016 31 Mar 2016 10-K 21 Mar 2018
Q4 2015 -$50.1M -$30.4M -$28.5M -1496% 01 Oct 2015 31 Dec 2015 10-K 31 Mar 2017
Q3 2015 -$21.6M -$508K +$2.04M +80.1% 01 Jul 2015 30 Sep 2015 10-K 31 Mar 2017
Q2 2015 -$23.6M -$2.62M -$7.35M -155% 01 Apr 2015 30 Jun 2015 10-K 31 Mar 2017
Q1 2015 -$16.3M -$16.5M -$16.2M -4347% 01 Jan 2015 31 Mar 2015 10-K 31 Mar 2017
Q4 2014 -$99K -$1.91M -$1.11M -140% 01 Oct 2014 31 Dec 2014 10-K 31 Mar 2017
Q3 2014 $1.02M -$2.55M -$1.54M -154% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015
Q2 2014 $2.56M $4.73M +$5.76M 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$3.2M -$372K +$686K +64.8% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q4 2013 -$3.89M -$794K +$2.71M +77.3% 01 Oct 2013 31 Dec 2013 10-K 31 Mar 2015
Q3 2013 -$6.6M -$1.01M -$906K -918% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2014
Q2 2013 -$5.69M -$1.03M -$316K -44.2% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014
Q1 2013 -$5.38M -$1.06M +$2.59M +71% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014
Q4 2012 -$7.96M -$3.51M -$1.13M -47.5% 01 Oct 2012 31 Dec 2012 10-K 31 Mar 2014
Q3 2012 -$6.84M -$98.7K +$2.4M +96.1% 01 Jul 2012 30 Sep 2012 10-Q 18 Nov 2013
Q2 2012 -$9.24M -$714K -$146K -25.7% 01 Apr 2012 30 Jun 2012 10-Q 15 Aug 2013
Q1 2012 -$9.09M -$3.65M -$3.63M -27324% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013
Q4 2011 -$5.46M -$2.38M 01 Oct 2011 31 Dec 2011 10-K 01 Apr 2013
Q3 2011 -$2.5M -$2.76M -1073% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$568K -$627K -1064% 01 Apr 2011 30 Jun 2011 10-Q/A 28 Sep 2012
Q1 2011 -$13.3K 01 Jan 2011 31 Mar 2011 10-Q/A 02 Oct 2012
Q3 2010 $257K 01 Jul 2010 30 Sep 2010 10-Q 21 Nov 2011
Q2 2010 $59K 01 Apr 2010 30 Jun 2010 10-Q/A 09 Sep 2011

Cocrystal Pharma, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$17.5M +$480K +2.67% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 -$18M +$20.9M +53.7% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 -$38.8M -$24.7M -174% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$14.2M -$4.54M -47% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023
2020 -$9.65M +$38.5M +80% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022
2019 -$48.2M +$879K +1.79% 01 Jan 2019 31 Dec 2019 10-K 17 Mar 2021
2018 -$49M -$48.4M -7901% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020
2017 -$613K +$74.3M +99.2% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019
2016 -$74.9M -$24.8M -49.4% 01 Jan 2016 31 Dec 2016 10-K 21 Mar 2018
2015 -$50.1M -$50M -50528% 01 Jan 2015 31 Dec 2015 10-K 21 Mar 2018
2014 -$99K +$3.79M +97.5% 01 Jan 2014 31 Dec 2014 10-K 31 Mar 2017
2013 -$3.89M +$4.08M +51.2% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015
2012 -$7.96M -$2.51M -45.9% 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014
2011 -$5.46M -$5.14M -1606% 01 Jan 2011 31 Dec 2011 10-K 01 Apr 2013
2010 -$320K 01 Jan 2010 31 Dec 2010 10-K 16 Apr 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.